secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001193125-24-003373
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera prices $275M public offering of common stock and pre-funded warrants
---------------------------------------------------------------------------

- Priced public offering of 2.25M shares at $25.25 and 8.64M pre-funded warrants at $25.2499; gross proceeds ~$275M.
- Underwriters' option for additional 1.63M shares exercised in full; net proceeds estimated ~$301.1M.
- Preliminary cash, cash equivalents and marketable securities of ~$436M as of Dec 31, 2023, excluding $15M Sanofi milestone.
- Cash runway expected into first half of 2027 based on current plans and offering proceeds.
- Offering led by Morgan Stanley, J.P. Morgan, and TD Cowen; close expected Jan 9, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312524003373/0001193125-24-003373-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312524003373/d103567d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003373

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer